Learning How to Fight Cancer Ep. 3: Dr. Stephen Noga on the Future of Dendritic Cell Therapy
In Episode 3 of Learning How to Fight Cancer, Matt Halpert sits down with Dr. Stephen Noga — a respected oncologist, immunologist, and former faculty member at Johns Hopkins — to explore why dendritic cell therapy, long considered a scientific dead end, may now be the key to treating advanced cancers.
With over 30 years of experience spanning academia, industry, and the FDA, Dr. Noga shares what drew him to Immunocine’s work, why he believes their double-loaded dendritic cell technology is the first real breakthrough in the field, and what it will take for immunotherapy to move from fringe to frontline.
Together, he and Dr. Halpert break down the limitations of today’s conventional care, the systemic failures within U.S. healthcare, and why combining rigorous science with true compassion is the only path forward for patients with limited options.
““We’ve been working with dendritic cells for decades. Couldn’t get them to do anything. But what Immunocine has done — this is the first time I’ve seen it actually work in people.””
Show Notes / Timestamps:
00:00 – Why dendritic cell therapy never worked — until now
02:54 – The rise of immunotherapy: From toxic drugs to targeted treatments
06:58 – What makes dendritic cells “the managers” of immune response
09:55 – Case study: Stage 4 prostate cancer and a dramatic PSA drop
14:20 – The myth of Mexico: Why Dr. Noga endorsed Immunocine’s clinic
21:34 – What Dr. Noga’s critical care nurse wife saw in Immunocine’s care model
28:14 – How today’s healthcare system fails doctors and patients alike
33:56 – The patient who went from stage 4 to playing with his kids again
38:16 – The future of cell therapy — and why Immunocine is just getting started
READ THIS NEXT
Learning How to Fight Cancer Ep. 6: Optimizing Metabolism to Lower Inflammation with Dr. Janet Maendel
In this episode of Learning How to Fight Cancer, Dr. Matt Halpert sits down with Dr. Janet Maendel, founder of Nurture & Restore Wellne
Read More
Three Years After Treatment Kevin Cox Remains Cancer-Free
Three years ago, Kevin was navigating one of the most uncertain times of his life. After a Stage 2C melanoma diagnosis and a recurrence that
Read More
Defying a 1% Prognosis: Pete’s Fight Against a Rare Brain Cancer
When Pete was diagnosed with a Grade 4 diffuse astrocytoma, doctors told him he had a 1% chance of being alive in eight months. Th
Read More
